| Jon B Olson, MD | |
|
21701 76th Ave W, #203, Edmonds, WA 98026-7536 | |
| (425) 774-5163 | |
| Not Available |
| Full Name | Jon B Olson |
|---|---|
| Gender | Male |
| Speciality | Pain Medicine - Pain Medicine |
| Location | 21701 76th Ave W, Edmonds, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487703922 | NPI | - | NPPES |
| 43512 | Other | WA | L&I |
| OL0950 | Other | REGENCE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | 00014086 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jon B Olson, MD Po Box 77814, Seattle, WA 98177-0814 Ph: () - | Jon B Olson, MD 21701 76th Ave W, #203, Edmonds, WA 98026-7536 Ph: (425) 774-5163 |
News Archive
The 19th annual Elton John AIDS Foundation Academy Awards Viewing Party hosted by Sir Elton John and David Furnish raised nearly $4 million for the fight against HIV/AIDS. The gala, which took place on Sunday, February 27, at the Pacific Design Center in Los Angeles, was co-sponsored by Chopard and Jo & Raffy Manoukian.
The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet, could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol. Caution, the ESC experts advise, should be displayed in the interpretation of the results.
Interleukin Genetics, Inc. announced today that the Company has signed an agreement with the University of Michigan to conduct a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics' PST genetic test.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company has closed a $50 million Series B venture financing. Participants in the funding were current investors in Lux Biosciences, HBM Bioventures, Novo A/S, Prospect Venture Partners and SV Life Sciences (SVLS), as well as SVLS' publicly traded fund, International Biotechnology Trust plc.
A newly-engineered strain of mice whose dividing cells express a fluorescent protein could open the door to new methods of regulating cell proliferation in humans.
› Verified 6 days ago
Dr. Todd John Baumeister, D.O. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 7500 212th St Sw, Suite 212, Edmonds, WA 98026 Phone: 425-744-6022 Fax: 425-744-0631 |